Details for Patent: 9,731,869

Which drugs does patent 9,731,869 protect, and when does it expire?

Patent 9,731,869 protects LAZANDA and is included in one NDA.

This patent has twenty-seven patent family members in twenty-four countries.

Summary for Patent: 9,731,869

Title:	Container
Abstract:	A container (100), comprising a thread (120) arranged around an opening (110) for engaging a corresponding thread (120) of a closure (400), more than four retention members (140) arranged around the opening (110), each retention member (140) having an end-face for abutting a member (510) on an interior surface of the closure (400) to impede unthreading of the closure (400), the retention members (140) being arranged such that a tangent (170) to each end-face of the retention members (140) intersects a plane (160, 350) bisecting the container (100) at an obtuse angle (171), wherein the retention members (140) are arranged in first and second groups, the first group (141, 410) comprising one retention member (140) having an end-face substantially parallel to the plane bisecting the container (100), and the second group (142, 420) comprising two or more retention members (140), the first and second groups being arranged on one side of the plane (160, 350), each in a respective quadrant of the container (100), the teeth of the second group (142, 420) have a first inter-tooth spacing, and a second inter-tooth spacing is provided between an end-face of the retention member of the first group (141, 410) and a first retention member of the second group (142, 420), and the second inter-tooth spacing is larger than the first inter-tooth spacing.
Inventor(s):	Walsh; Philip (Bristol, GB), Watts; Peter (Nottingham, GB)
Assignee:	Archimedes Development Limited (Nottingham, GB)
Application Number:	13/983,400
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,731,869

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-001	Jun 30, 2011		DISCN	Yes	No			Y
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-003	Dec 21, 2015		DISCN	Yes	No			Y
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-002	Jun 30, 2011		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 9,731,869

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	11153387	Feb 4, 2011

PCT Information
PCT Filed	January 26, 2012	PCT Application Number:	PCT/GB2012/050163
PCT Publication Date:	August 09, 2012	PCT Publication Number:	WO2012/104607

International Family Members for US Patent 9,731,869

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012213170
Brazil	112013019834
Canada	2824385